GO:0005504 fatty acid binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0005504 fatty acid binding is a molecular function defined as binding to a fatty acid, an aliphatic monocarboxylic acid liberated from naturally occurring fats and oils by hydrolysis.
• Fatty acid binding is mediated by fatty acid-binding proteins (FABPs), a family of small intracellular lipid chaperones that solubilize hydrophobic fatty acids and direct them to metabolic and signaling pathways.
• FABPs are tissue-specific: FABP1 (liver), FABP2 (intestine), FABP3 (heart), FABP4 (adipocytes), FABP5 (epidermis/psoriasis), FABP7 (brain), and others, each with distinct ligand preferences and functions.
• Dysregulated fatty acid binding contributes to cancer, metabolic disorders, and neurological conditions, making FABPs attractive therapeutic targets.
• CRISPR-based knockout, point mutation, knock-in, and overexpression models enable causal interrogation of fatty acid binding in health and disease.
• EDITGENE provides end-to-end CRISPR services to generate custom cell models for studying fatty acid binding and its role in disease.
Description
Fatty acid binding (GO:0005504) is a molecular function that enables a protein to bind a fatty acid, an aliphatic monocarboxylic acid liberated from naturally occurring fats and oils by hydrolysis. This function is essential for the solubilization, transport, and metabolic channeling of hydrophobic fatty acids within cells. The primary mediators of this function are the fatty acid-binding proteins (FABPs), a family of small (14–15 kDa) intracellular proteins that bind long-chain fatty acids and other lipophilic ligands with high affinity. FABPs are expressed in a tissue-specific manner and are involved in lipid uptake, trafficking, and signaling, as well as in the regulation of gene expression and cell growth. Because fatty acid binding is central to lipid homeostasis, its dysregulation has been implicated in a wide range of human diseases, including cancer, diabetes, atherosclerosis, and neurodegenerative disorders. Understanding the molecular mechanisms, regulatory networks, and disease associations of fatty acid binding is therefore of high interest to researchers in metabolism, oncology, and neuroscience. This article provides a comprehensive overview of GO:0005504, covering its definition, biological significance, key genes, research models, and methods for experimental investigation.
fatty acid binding At A Glance
| GO ID | GO:0005504 |
|---|---|
| GO term | fatty acid binding |
| Ontology | molecular_function |
| Synonym | None |
| Major function | Binding to fatty acids, enabling their solubilization, transport, and metabolic channeling |
| Major protein family | Fatty acid-binding proteins (FABPs), including FABP1–FABP12, and plasma albumin |
| Tissue distribution | Tissue-specific expression (e.g., liver, intestine, heart, adipose, brain, epidermis) |
| Ligand specificity | Long-chain fatty acids, e.g., palmitic acid, oleic acid, arachidonic acid; some FABPs also bind retinoids and eicosanoids |
| Associated diseases | Cancer, metabolic syndrome, cardiovascular disease, neurodegenerative disorders |
What Is GO:0005504?
According to the Gene Ontology, GO:0005504 fatty acid binding is defined as the binding to a fatty acid, an aliphatic monocarboxylic acid liberated from naturally occurring fats and oils by hydrolysis. This molecular function is typically executed by fatty acid-binding proteins (FABPs), which non-covalently and reversibly bind fatty acids and other hydrophobic ligands. The binding event facilitates the solubilization of fatty acids in the aqueous cellular environment and their directed transport to specific organelles or enzymes for metabolic conversion or signaling.
Why Is fatty acid binding Important in Cell Biology?
Fatty acid binding is a fundamental molecular function that governs lipid homeostasis, energy metabolism, and cellular signaling. By controlling the intracellular availability of fatty acids, FABPs influence diverse processes such as fatty acid oxidation, lipid synthesis, membrane remodeling, and the regulation of transcription factors like PPARs. Dysregulation of fatty acid binding has been linked to the pathogenesis of numerous diseases, including cancer, where FABPs promote tumor growth and metastasis, and metabolic disorders such as diabetes and atherosclerosis. Moreover, FABPs are emerging as promising therapeutic targets and biomarkers, underscoring the importance of understanding this function at the molecular, cellular, and organismal levels.
• Fatty acid binding enables the solubilization and intracellular transport of hydrophobic fatty acids, which are otherwise insoluble in aqueous environments.
• FABPs facilitate metabolic channeling of fatty acids to specific pathways such as beta-oxidation, lipid synthesis, and signaling.
• Fatty acid binding proteins regulate gene expression by delivering ligands to nuclear receptors like PPARs.
• Dysregulated fatty acid binding is implicated in cancer progression, including proliferation, migration, and metastasis.
• FABPs play critical roles in intestinal lipid absorption and chylomicron assembly, with FABP2 as a key player.
• In the nervous system, FABPs (e.g., FABP3, FABP5, FABP7) influence neuronal development, synaptic function, and mental health.
• Fatty acid binding to plasma albumin is essential for the transport of free fatty acids in the bloodstream.
• Genetic manipulations of FABPs in mice have revealed their roles in energy homeostasis, insulin sensitivity, and atherosclerosis.
• FABPs are potential therapeutic targets for multiple myeloma and other cancers.
• Understanding fatty acid binding mechanisms can inform the development of drugs targeting lipid metabolism.
Molecular Mechanism of fatty acid binding
Ligand recognition and binding pocket
In simple terms: FABPs have a pocket that fits fatty acids like a hand in a glove.
Fatty acid-binding proteins (FABPs) adopt a beta-barrel structure with a central cavity that accommodates a single fatty acid molecule. The binding pocket is lined with hydrophobic residues that interact with the aliphatic chain of the fatty acid, while polar residues at the entrance interact with the carboxylate head group. This architecture allows FABPs to bind long-chain fatty acids with high affinity and selectivity.
Conformational changes and ligand entry
In simple terms: The protein opens and closes to let the fatty acid in and out.
Ligand binding induces conformational changes in FABPs, particularly in the portal region, which regulates the entry and exit of fatty acids. These dynamic motions are essential for the reversible binding and release of fatty acids, enabling FABPs to act as intracellular carriers.
Fatty acid transport and targeting
In simple terms: FABPs act like taxis that deliver fatty acids to where they are needed.
Once bound, FABPs facilitate the transport of fatty acids to specific cellular destinations, such as mitochondria for beta-oxidation, the endoplasmic reticulum for lipid synthesis, or the nucleus for gene regulation. This targeting is mediated by protein-protein interactions with downstream effectors and is critical for metabolic channeling.
Regulation of fatty acid binding
In simple terms: The amount and activity of FABPs are controlled by the cell.
Fatty acid binding is regulated at multiple levels, including transcriptional control by nuclear receptors (e.g., PPARs), post-translational modifications, and competition with other lipid-binding proteins. For example, FABP4 expression is induced during adipocyte differentiation, while FABP5 is upregulated in response to growth factors and in cancer.
Interaction with plasma albumin
In simple terms: In blood, albumin carries fatty acids instead of FABPs.
In the bloodstream, fatty acids are bound to plasma albumin, which serves as a carrier for free fatty acids. This binding is distinct from intracellular FABPs but is also covered by the GO term fatty acid binding. Albumin binding sites accommodate multiple fatty acids and facilitate their transport to tissues.
Key Genes Involved in GO:0005504 fatty acid binding
The following genes encode proteins that mediate fatty acid binding (GO:0005504) and are widely studied in metabolism, cancer, and neuroscience.
| Gene | Major Role | Research Relevance |
|---|---|---|
| FABP1 | Liver-type FABP; binds fatty acids and other lipophilic ligands in hepatocytes | Liver metabolism, fatty liver disease, drug transport |
| FABP2 | Intestinal FABP; involved in dietary fat absorption and chylomicron assembly | Intestinal lipid metabolism, insulin resistance, obesity |
| FABP3 | Heart-type FABP; highly expressed in cardiac and skeletal muscle | Cardiac energy metabolism, heart failure, biomarker for myocardial injury |
| FABP4 | Adipocyte FABP; regulates lipolysis and inflammation | Obesity, insulin resistance, atherosclerosis, cancer |
| FABP5 | Epidermal FABP; binds fatty acids and retinoic acid | Psoriasis, cancer progression, metabolic syndrome |
| FABP6 | Ileal lipid-binding protein; involved in bile acid and fatty acid transport | Bile acid metabolism, intestinal disorders |
| FABP7 | Brain-type FABP; expressed in glial cells and neural stem cells | Neurodevelopment, Alzheimer's disease, glioma |
| FABP8 | Myelin FABP; found in peripheral nervous system myelin | Myelin maintenance, peripheral neuropathies |
| FABP9 | Testis FABP; involved in spermatogenesis | Male fertility, sperm function |
| FABP12 | Retinal FABP; expressed in retina and other tissues | Retinal degeneration, lipid metabolism |
| ALB | Plasma albumin; binds free fatty acids in circulation | Fatty acid transport, drug binding, hypoalbuminemia |
| PMDCI | Plasma membrane fatty acid-binding protein (FABPpm); involved in fatty acid uptake | Cardiac and skeletal muscle fatty acid uptake |
| CRABP1 | Cellular retinoic acid-binding protein 1; binds retinoic acid, a fatty acid derivative | Retinoid signaling, development, cancer |
| CRABP2 | Cellular retinoic acid-binding protein 2; delivers retinoic acid to nuclear receptors | Retinoid signaling, differentiation, cancer |
| ACBP | Acyl-CoA-binding protein; binds acyl-CoA esters | Lipid metabolism, acyl-CoA pool regulation |
| H-FABP | Heart-type FABP (same as FABP3); used as cardiac biomarker | Myocardial infarction diagnosis |
| L-FABP | Liver-type FABP (same as FABP1); binds fatty acids and bile acids | Liver injury biomarker, fatty liver disease |
How Is fatty acid binding Regulated?
Fatty acid binding is regulated at transcriptional, post-transcriptional, and post-translational levels. Transcription of FABP genes is controlled by nuclear receptors such as PPARs, which are activated by fatty acids and their derivatives. For example, FABP4 expression is induced during adipogenesis and by PPARγ agonists, while FABP5 is upregulated by growth factors and in cancer cells. Post-translational modifications, including phosphorylation, can modulate FABP localization and ligand binding affinity. Additionally, the availability of fatty acids and their metabolites influences FABP expression through feedback mechanisms, ensuring cellular lipid homeostasis.
fatty acid binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| FABP5 | Cancer (prostate, breast, hepatocellular carcinoma) | Knockout and overexpression in cancer cell lines; xenograft models |
| FABP4 | Obesity, insulin resistance, atherosclerosis | Adipocyte-specific knockout mice; CRISPR KO in 3T3-L1 cells |
| FABP3 | Cardiovascular disease, myocardial infarction | Cardiomyocyte-specific KO; point mutation to alter ligand binding |
| FABP7 | Neurological disorders (Alzheimer's, schizophrenia) | Neural stem cell KO; knock-in of disease-associated variants |
| FABP2 | Metabolic syndrome, insulin resistance | Intestinal epithelial cell models; knock-in of polymorphic variants |
Fatty acid binding in cancer
Dysregulated fatty acid binding is increasingly recognized as a hallmark of cancer. FABP5 is overexpressed in various cancers, including prostate, breast, and hepatocellular carcinoma, where it promotes cell proliferation, survival, and metastasis. FABP4 has been implicated in ovarian and breast cancer, contributing to tumor growth and angiogenesis. In multiple myeloma, FABPs support tumor cell survival and are being explored as therapeutic targets. The oncogenic roles of FABPs are often linked to their ability to deliver fatty acids for energy production and signaling, as well as to activate PPARβ/δ and other nuclear receptors.
Fatty acid binding in metabolic disorders
Alterations in fatty acid binding contribute to metabolic diseases such as type 2 diabetes, obesity, and atherosclerosis. FABP2 polymorphisms have been associated with insulin resistance and dyslipidemia, affecting intestinal fat absorption. FABP4 is elevated in obesity and insulin resistance, and its inhibition improves glucose tolerance and reduces atherosclerosis in preclinical models. FABP1 in the liver is involved in fatty liver disease and may serve as a biomarker for liver injury.
Fatty acid binding in neurological and psychiatric disorders
In the nervous system, FABPs regulate lipid metabolism and signaling, influencing neuronal development and function. FABP3, FABP5, and FABP7 are expressed in the brain and have been linked to mental conditions such as schizophrenia, depression, and anxiety. FABP7 is important for neural stem cell proliferation and is associated with Alzheimer's disease pathology. These findings highlight the importance of fatty acid binding in brain health and disease.
Fatty acid binding in cardiovascular disease
Heart-type FABP (FABP3) is highly expressed in cardiomyocytes and is released into the circulation upon myocardial injury, making it a useful biomarker for acute myocardial infarction. FABP4 and FABP5 have also been implicated in atherosclerosis and endothelial dysfunction, linking fatty acid binding to cardiovascular risk.
From fatty acid binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of FABP5 affect cancer cell proliferation? | FABP5 knockout in cancer cell lines (e.g., PC-3, MCF-7) using CRISPR-Cas9 |
| How does a specific FABP4 mutation alter ligand binding? | Point mutation knock-in in adipocytes or HEK293 cells |
| What is the effect of FABP3 overexpression on cardiomyocyte lipid metabolism? | Overexpression of FABP3 in iPSC-derived cardiomyocytes |
| Can we track FABP7 localization in live neurons? | Knock-in of fluorescent tag (e.g., GFP) at the FABP7 locus |
| Does FABP2 polymorphism affect intestinal fat absorption? | Knock-in of human FABP2 variants in intestinal organoids |
| What genes synergize with FABP5 in tumor growth? | CRISPR library screening in FABP5-dependent cancer cells |
How to Study the fatty acid binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR-Cas9 knockout | Loss of gene function | Studying FABP roles in cancer, metabolism |
| Point mutation knock-in | Effect of specific mutations | Structure-function analysis of FABP ligand binding |
| Overexpression | Gain of function | Investigating FABP-driven phenotypes |
| Tagged knock-in | Protein localization and interactions | Live-cell imaging, proteomics |
| CRISPR library screening | Genome-wide gene function | Identifying synthetic lethal partners of FABPs |
| RNA-seq | Transcriptional changes | Pathway analysis upon FABP modulation |
| Proteomics | Protein expression and interactions | Identifying FABP binding partners |
| Lipidomics | Lipid species profiling | Assessing fatty acid uptake and metabolism |
CRISPR-Cas9 knockout
CRISPR-Cas9 knockout is a powerful method to study the loss-of-function of FABP genes. By designing guide RNAs targeting the coding sequence, researchers can generate cell lines or animal models with complete ablation of fatty acid binding activity. This approach has been used to demonstrate the role of FABP4 in adipocyte lipolysis and FABP5 in cancer cell survival.
Point mutation and knock-in
Point mutations can be introduced via homology-directed repair (HDR) to study the impact of specific amino acid changes on fatty acid binding affinity and specificity. For example, mutations in the ligand-binding pocket of FABP3 can alter its interaction with fatty acids, providing insights into structure-function relationships. Knock-in of disease-associated variants (e.g., FABP2 A54T) in cell models helps elucidate their functional consequences.
Overexpression and tagged knock-in
Overexpression of FABPs using lentiviral or CRISPR-based activation allows researchers to study gain-of-function effects on lipid metabolism and signaling. Tagged knock-in (e.g., GFP or FLAG) enables live-cell imaging and proteomic analysis of FABP interactions and localization.
CRISPR library screening and bioinformatics
Genome-wide CRISPR knockout or activation screens can identify genes that modulate fatty acid binding and its downstream pathways. Combined with bioinformatics analysis (e.g., RNA-seq, pathway enrichment), these screens reveal novel regulators and therapeutic targets.
How CRISPR Can Be Used to Study GO:0005504 fatty acid binding
Knockout
CRISPR knockout of FABP genes is used to study their essential functions in lipid metabolism, cell growth, and differentiation. For example, FABP4 knockout mice exhibit reduced adiposity and improved insulin sensitivity. In cancer cells, FABP5 knockout reduces proliferation and migration.
Point Mutation
Point mutations in FABP genes can be introduced to dissect the contribution of specific residues to fatty acid binding. This is particularly useful for studying natural variants, such as the FABP2 A54T polymorphism associated with insulin resistance.
Knock-in
Knock-in of reporter tags or disease-associated alleles allows precise tracking and functional analysis of FABPs. For instance, knock-in of a fluorescent tag at the FABP7 locus enables visualization of its expression in neural cells.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression is used to elevate FABP levels and study gain-of-function phenotypes, such as enhanced fatty acid uptake and tumor growth.
How EDITGENE Supports fatty acid binding Research
Researchers studying fatty acid binding-related genes often need to determine whether a candidate gene is causally involved in a specific phenotype, such as cancer cell proliferation or lipid accumulation. Generating reliable CRISPR models is essential for such functional studies.
Contact EDITGENE today to design your custom CRISPR model for fatty acid binding research.
Frequently Asked Questions About fatty acid binding
What is fatty acid binding (GO:0005504)?
Fatty acid binding is a molecular function defined as binding to a fatty acid, an aliphatic monocarboxylic acid liberated from naturally occurring fats and oils by hydrolysis. It is primarily mediated by fatty acid-binding proteins (FABPs).
What genes are involved in fatty acid binding?
Genes encoding fatty acid-binding proteins include FABP1, FABP2, FABP3, FABP4, FABP5, FABP6, FABP7, FABP8, FABP9, FABP12, and ALB (albumin).
How does fatty acid binding work?
FABPs bind fatty acids in a central cavity and undergo conformational changes to transport them to specific cellular destinations, such as mitochondria or the nucleus.
Why is fatty acid binding important in cancer?
FABPs, particularly FABP5 and FABP4, are overexpressed in various cancers and promote tumor growth, survival, and metastasis by delivering fatty acids for energy and signaling.
What diseases are associated with fatty acid binding proteins?
Dysregulated fatty acid binding is linked to cancer, obesity, insulin resistance, atherosclerosis, and neurological disorders.
How can I study fatty acid binding using CRISPR?
CRISPR knockout, point mutation, knock-in, and overexpression models allow functional interrogation of FABP genes in relevant cell types.
What is the role of FABP4 in metabolism?
FABP4 is expressed in adipocytes and regulates lipolysis and inflammation; its inhibition improves insulin sensitivity and reduces atherosclerosis in mice.
Which FABP is a biomarker for heart attack?
Heart-type FABP (FABP3) is released into the blood upon myocardial injury and is used as an early biomarker for acute myocardial infarction.
How does FABP5 contribute to psoriasis?
FABP5 is upregulated in psoriatic skin and is involved in keratinocyte differentiation and lipid metabolism, making it a potential therapeutic target.
What services does EDITGENE offer for fatty acid binding research?
EDITGENE provides CRISPR knockout, point mutation, knock-in, overexpression cell models, CRISPR library screening, and bioinformatics services to study fatty acid binding genes.
Conclusion
Fatty acid binding (GO:0005504) is a fundamental molecular function that governs lipid homeostasis, energy metabolism, and cellular signaling. The fatty acid-binding protein family mediates this function in a tissue-specific manner, and its dysregulation is implicated in cancer, metabolic disorders, and neurological diseases. Advances in CRISPR-based genome editing have enabled precise functional studies of FABP genes, offering new insights into their roles in health and disease. Targeting fatty acid binding pathways holds promise for therapeutic development, and continued research will further elucidate the complex biology of this essential function.
References
- 1. George Warren W et al.. 2023. The emerging role of fatty acid binding protein 5 (FABP5) in cancers.. Drug Discov Today 28(7):103628 PMID: 37230284
- 2. Huang X et al.. 2022. Intestinal fatty acid binding protein: A rising therapeutic target in lipid metabolism.. Prog Lipid Res 87:101178 PMID: 35780915
- 3. Spector AA. 1975. Fatty acid binding to plasma albumin.. J Lipid Res 16(3):165-79 PMID: 236351
- 4. Schaap FG et al.. 1998. Fatty acid-binding proteins in the heart.. Mol Cell Biochem 180(1-2):43-51 PMID: 9546629
- 5. Haunerland NH et al.. 2004. Fatty acid-binding proteins--insights from genetic manipulations.. Prog Lipid Res 43(4):328-49 PMID: 15234551
- 6. Matsumata M et al.. 2016. Fatty acid binding proteins and the nervous system: Their impact on mental conditions.. Neurosci Res 102:47-55 PMID: 25205626
- 7. Glatz JF et al.. 1990. Nomenclature of fatty acid-binding proteins.. Mol Cell Biochem 98(1-2):231-5 PMID: 2266964
- 8. Fairfield H et al.. 2023. The hope for targeting fatty acid binding proteins in multiple myeloma.. Oncotarget 14:612-613 PMID: 37335289
